Research Article
Efficacy and Safety of Botulinum Toxin Type A for Limb Spasticity after Stroke: A Meta-Analysis of Randomized Controlled Trials
Table 1
Baseline characteristics of studies included in the current systematic review and meta-analysis.
| Study | Country | Sample size | Mean age | Percentage male (%) | Time since event | Spasticity sites | Dose of BTXA | Injection technique | Duration of follow-up | Jadad score |
| Simpson 1996 [27] | US | 37 | 59.0 | 43.2 | 37.0 months | Upper | Botox 75, 150, 300 units | EMG | 16.0 weeks | 2 |
| Hesse 1998 [28] | Germany | 24 | 52.3 | 79.2 | 7.5 months | Upper | Dysport 1000 units | EMG | 12.0 weeks | 3 |
| Smith 2000 [29] | UK | 25 | 51.9 | 40.0 | >12.0 months | Upper | Dysport 500, 1000, 1500 units | NA | 12.0 weeks | 4 |
| Bakheit 2000 [30] | UK | 83 | 62.5 | 62.7 | >3.0 months | Upper | Dysport 500, 1000, 1500 units | Anatomical landmarks | 16.0 weeks | 4 |
| Bhakta 2000 [31] | UK | 40 | 57.0 | 57.5 | 37.2 months | Upper | Dysport 1000 units | Anatomical landmarks | 12.0 weeks | 5 |
| Brashear 2002 [32] | US | 126 | 61.5 | 50.0 | 56.4 months | Upper | Botox 200-240 units | NA | 12.0 weeks | 4 |
| Childers 2004 [33] | US | 91 | 60.0 | 67.0 | 25.8 months | Upper | Botox 90, 180, 360 units | EMG | 9.0 weeks | 5 |
| Yelnik 2007 [34] | France | 20 | 54.1 | 75.0 | 17.0 months | Upper | Dysport 500 units | ES | 4.0 weeks | 3 |
| Simpson 2009 [35] | US | 39 | 51.9 | 53.8 | > 24 hours | Upper | Botox 500 units | ES | 6.0 weeks | 4 |
| Meythaler 2009 [36] | US | 21 | 53.3 | 71.4 | > 6.0 months | Upper | Botox 300-400 units | EMG | 12.0 weeks | 4 |
| Mccrory 2009 [37] | Australia | 96 | 59.6 | 60.4 | 70.8 months | Upper | Dysport 750-1000 units | EMG or ES | 20.0 weeks | 5 |
| Kanovsky 2009 [38] | Germany | 148 | 55.6 | 64.2 | 55.0 months | Upper | Botox 400 units | EMG | 12.0 weeks | 5 |
| Kaji 2010 [39] | Japan | 109 | 63.2 | 67.9 | 82.9 months | Upper | Botox 120-150, 200-240 units | EMG nerve stimulator | 12.0 weeks | 5 |
| Rosales 2012 [40] | Hong Kong, Malaysia, the Philippines, Singapore, and Thailand | 163 | 55.1 | 66.9 | 1.7 months | Upper | Botox 500 units | NA | 24.0 weeks | 5 |
| Wolf 2012 [41] | US | 25 | 49.3 | 60.0 | 3.0-24.0 months | Upper | Dysport 300 units | NA | 12.0 weeks | 3 |
| Gracies 2015 [42] | Europe and the US | 238 | 52.8 | 64.3 | 61.2 months | Upper | Dysport 500, 1000 units | ES | 12.0 weeks | 5 |
| Elovic 2016 [43] | US | 317 | 56.0 | 46.4 | 28.0 months | Upper | Xeomin 400 units | EMG and/or ES ultrasound | 4.0 weeks | 5 |
| Prazeres 2018 [44] | Brazil | 40 | 52.3 | 60.0 | 33.1 months | Upper | Dysport NA | NA | 24.0 weeks | 4 |
| Burbaud 1996 [45] | France | 23 | 52.5 | 69.6 | 23.5 months | Lower | Dysport 1000 units | EMG | 12.0 weeks | 3 |
| Pittock 2003 [46] | Ireland | 234 | 55.5 | NA | > 3.0 months | Lower | Dysport 500, 1000, 1500 units | NA | 12.0 weeks | 4 |
| Kaji 2010 [47] | Japan | 120 | 62.5 | 80.0 | > 6.0 months | Lower | Botox 300 units | EMG | 12.0 weeks | 4 |
| Dunne 2012 [48] | Australia | 83 | 58.4 | 76.5 | 40.8 months | Lower | Botox 200, 300 units | EMG or ES | 12.0 weeks | 5 |
| Fietzek 2014 [49] | Germany | 52 | 54.3 | 57.7 | < 3.0 months | Lower | Botox 230 units | NA | 12.0 weeks | 4 |
| Tao 2015 [50] | China | 23 | 56.5 | 65.2 | < 1.5 months | Lower | Botox 200 units | EMG | 8.0 weeks | 3 |
| Ding 2015 [51] | China | 68 | 63.5 | 48.5 | 15.9 months | Lower | Lanzhou Institute of Biological Products 100 units/ampule | Electrical nerve stimulator | 24.0 weeks | 3 |
| Ding 2017 [52] | China | 80 | 61.9 | 51.3 | 4.2 months | Lower | Lanzhou Institute of Biological Products 350 units | Electrical nerve stimulator | 12.0 weeks | 3 |
| Wein [53] | North America, Europe, Russia, the United Kingdom, 66 and Asia 5 | 468 | 56.5 | 64.7 | 64.3 months | Lower | Botox ≤ 400 units | EMG and/or ES ultrasound | 6.0 weeks | 5 |
|
|
EMG: electromyography; ES: electrical stimulation; NA: not available; UK: United Kingdom; US: United States. |